Early overactivation of non-muscle myosin II during adaptation to combined BRAF and MEK inhibitors in dedifferentiating cutaneous melanomas
Andrea Garcia-Perez, Lucía Sanchez-Garcia, Marta Duran-Renieblas, Federica Sella, Silvia Novo-Acedo, Angel Delgado-Lopez, Adrian Barreno, Judith Gracia, Christopher Rios, Erica J. Young, Laszlo Radnai, Clara Diaz-Utrilla, Julia M. Martinez-Gomez, Rosa M. Marti, Marta C. Sallan, , José Luis Orgaz
This study shows that non-muscle myosin II overactivation occurs in dedifferentiating melanomas adapting to BRAF and MEK inhibitors, and targeting NMII with BMi reduces drug-tolerant persister cell survival.
bioRxiv · Dec 3, 2025 · PreprintCancer Biology